COMPOSITION | |
---|---|
Omega 3 6 9 Fatty Acid | – |
Omega 3 6 9 Fatty Acid
OMEGAVIB 369
SPECIFICATION | |
---|---|
FORM | CAPSULE | SOFTGEL |
PACKING | 10x1x10 | 10X10 |
PACKING TYPE | BLISTER | |
MRP | 1200 | 1240 |
DESCRIPTION
Omega-3 fatty acids are polyunsaturated fatty acids (PUFAs) with a double bond at the third carbon atom from the end of the carbon chain. The three types of omega-3 fatty acids involved in human physiology are α-linolenic acid (ALA) (found in plant oils), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) (both commonly found in fish oil that originally come from microalgae that is further consumed by phytoplankton, a source of diet for fish). Omega-3 fatty acids play a critical role in metabolism and cellular function and they are available as daily supplements. On September 8, 2004, the U.S. Food and Drug Administration gave “qualified health claim” status to EPA and DHA omega-3 fatty acids. Therapeutic products containing omega-3 fatty acid and its derivatives for treatment of hypertriglyceridemia include Lovaza, Omtryg, Epanova, and Vascepa.
SIDE EFFECTS
Some adverse effects experienced in patients include gastrointestinal disturbances such as vomiting and constipation, metabolic disorders and skin reactions.
INDICATION
Provided as daily supplements. Aa preparation of omega-3-acid ethyl esters is licensed in UK for prevention of recurrent events after myocardial infarction in addition to treatment of hypertriglyceridaemia.